PPBT
Purple BiotechPPBT
PPBT
About: Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Employees: 7
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.01% less ownership
Funds ownership: 0.02% [Q4 2024] → 0.01% (-0.01%) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
36% less funds holding
Funds holding: 14 [Q4 2024] → 9 (-5) [Q1 2025]
64% less capital invested
Capital invested by funds: $378K [Q4 2024] → $134K (-$244K) [Q1 2025]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for PPBT.
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Purple Biotech Reports First Quarter 2025 Financial Results
Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025
Neutral
GlobeNewsWire
1 month ago
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction
Neutral
GlobeNewsWire
1 month ago
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
REHOVOT, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today that two posters reporting new NT219 data being presented at the American Association for Cancer Research (AACR 2025) Annual Meeting on Sunday and Monday, April 27-28, 2025.
Neutral
GlobeNewsWire
3 months ago
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Completed successful clinical trials for CM24 and NT21 9 oncology assets , demonstrating clinical benefit s and identifying potential biomarkers
Neutral
GlobeNewsWire
3 months ago
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
Neutral
GlobeNewsWire
6 months ago
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 472,668 of the Company's American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS.
Positive
Zacks Investment Research
6 months ago
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Neutral
GlobeNewsWire
6 months ago
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company's American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered direct offering. The closing of the offering is expected to occur on or about December 4, 2024, subject to the satisfaction of customary closing conditions.
Positive
Benzinga
6 months ago
Why Is Purple Biotech Stock Trading Higher On Monday?
On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).
Neutral
GlobeNewsWire
7 months ago
Purple Biotech Reports Third Quarter 2024 Financial Results
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced financial results for the three and nine months ended September 30, 2024.
Charts implemented using Lightweight Charts™